Ryan T. Muir, Sophie Stukas, Jennifer G. Cooper, Andrew E. Beaudin, Cheryl R. McCreary, Myrlene Gee, Krista Nelles, Nikita Nukala, Janina Valencia, Kristopher M Kirmess, Sandra E. Black, Michael D. Hill, Richard Camicioli, Cheryl L. Wellington, Eric. E Smith
{"title":"Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls","authors":"Ryan T. Muir, Sophie Stukas, Jennifer G. Cooper, Andrew E. Beaudin, Cheryl R. McCreary, Myrlene Gee, Krista Nelles, Nikita Nukala, Janina Valencia, Kristopher M Kirmess, Sandra E. Black, Michael D. Hill, Richard Camicioli, Cheryl L. Wellington, Eric. E Smith","doi":"10.1101/2024.09.04.24313038","DOIUrl":null,"url":null,"abstract":"<strong>INTRODUCTION</strong> Cerebral Amyloid Angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ<sub>42/40,</sub> phosphorylated-tau (p-tau), neurofilament light chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) differ in CAA and their potential to discriminate Boston Criteria 2.0 probable CAA from healthy controls.","PeriodicalId":501367,"journal":{"name":"medRxiv - Neurology","volume":"2013 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.04.24313038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION Cerebral Amyloid Angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ42/40, phosphorylated-tau (p-tau), neurofilament light chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) differ in CAA and their potential to discriminate Boston Criteria 2.0 probable CAA from healthy controls.